🇺🇸 FDA

Company profile · Sponsor

ENANTA

ENANTA PHARMACEUTICALS INC

ENTA · NYSE pharma WATERTOWN, MA, USA
Pipeline
24
Drugs
0
Patents
8

Quick answer

ENANTA (ENTA) is a pharma company. headquartered in WATERTOWN, MA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker ENTA
Exchange NYSE
Company type pharma
Headquarters WATERTOWN, MA, USA
SEC CIK 0001177648

Pipeline (24)

Search pipeline →

  1. EDP-235

    ENANTA

    COVID-19

    phase 2 small molecule completed

    3 trials

  2. EDP-305 1 mg

    ENANTA

    Primary Biliary Cholangitis

    phase 2 small molecule completed

    1 trial

  3. EDP-305 1.5 mg

    ENANTA

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule terminated

    1 trial

  4. EDP-305 Dose 1

    ENANTA

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  5. EDP-323 Dose Regimen 1

    ENANTA

    RSV Infection

    phase 2 small molecule completed

    1 trial

  6. EDP-420 / Duration of Treatment - 3 days

    ENANTA

    Community Acquired Pneumonia

    phase 2 small molecule active

    1 trial

  7. EDP-938

    ENANTA

    Respiratory Syncytial Virus (RSV)

    phase 2 small molecule completed

    2 trials

  8. EDP-938

    ENANTA

    Respiratory Syncytial Virus Infections

    phase 2 small molecule terminated

    1 trial

  9. EDP-938

    ENANTA

    Respiratory Syncytial Virus

    phase 2 small molecule completed

    1 trial

  10. EDP-938

    ENANTA

    RSV Infection

    phase 2 small molecule completed

    6 trials

  11. EDP-938 Dose 1

    ENANTA

    RSV Infection

    phase 2 small molecule completed

    1 trial

  12. EDP-938, EDP-938 Placebo tablets

    ENANTA

    Respiratory syncytial virus (RSV)

    phase 2 small molecule active

    1 trial

  13. zelicapavir

    ENANTA

    RSV Infection

    phase 2 small molecule active

    1 trial

  14. DEB025

    ENANTA

    Hepatitis C Virus

    phase 1 small molecule completed

    1 trial

  15. EDP 305

    ENANTA

    Presumptive NAFLD

    phase 1 small molecule completed

    1 trial

  16. EDP 305

    ENANTA

    NASH

    phase 1 small molecule completed

    1 trial

  17. EDP-235

    ENANTA

    SARS CoV 2 Infection

    phase 1 small molecule completed

    1 trial

  18. EDP-297

    ENANTA

    NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis

    phase 1 small molecule completed

    1 trial

  19. EDP-305

    ENANTA

    NASH - Nonalcoholic Steatohepatitis

    phase 1 small molecule completed

    2 trials

  20. EDP-322

    ENANTA

    MRSA, SSTI

    phase 1 small molecule completed

    1 trial

  21. EDP-322

    ENANTA

    Skin and Soft Tissue Infections

    phase 1 small molecule completed

    1 trial

  22. EDP-323

    ENANTA

    RSV Infection

    phase 1 small molecule completed

    3 trials

  23. EDP-494

    ENANTA

    Hepatitis C

    phase 1 small molecule completed

    1 trial

  24. EDP-514

    ENANTA

    Hepatitis B

    phase 1 small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 12384753

    17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12358921

    Antiviral heterocyclic compounds

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12297209

    Benzodiazepine derivatives as RSV inhibitors

    Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12281140

    Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12268694

    Combination pharmaceutical agents as RSV inhibitors

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12264159

    Functionalized heterocycles as antiviral agents

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12162857

    Antiviral compounds

    Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12145941

    Heterocyclic antiviral agents

    Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is ENANTA?

ENANTA (ENTA) is a pharma company. headquartered in WATERTOWN, MA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does ENANTA sponsor?

We track 24 ClinicalTrials.gov-linked programs for ENANTA, including EDP-235 and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does ENANTA company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.